Akynzeo netupitant/palonosetron regulatory update

FDA approved Akynzeo netupitant/palonosetron from Helsinn to treat nausea and vomiting in patients undergoing cancer chemotherapy. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist. Palonosetron is marketed to prevent chemotherapy-induced nausea and vomiting (CINV) under the names Aloxi, Paloxi and Onicit in more than 60 countries worldwide. Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) and Helsinn will co-promote Akynzeo in the U.S. ...